Your browser is no longer supported. Please, upgrade your browser.
ILMN Illumina, Inc. daily Stock Chart
Illumina, Inc.
IndexS&P 500 P/E56.09 EPS (ttm)6.34 Insider Own0.40% Shs Outstand147.00M Perf Week-6.93%
Market Cap52.37B Forward P/E46.29 EPS next Y7.68 Insider Trans-12.35% Shs Float146.55M Perf Month-4.55%
Income942.00M PEG5.26 EPS next Q0.67 Inst Own92.30% Short Float2.25% Perf Quarter14.78%
Sales3.56B P/S14.73 EPS this Y19.70% Inst Trans-0.28% Short Ratio3.66 Perf Half Y20.85%
Book/sh31.53 P/B11.28 EPS next Y28.52% ROA13.20% Target Price343.86 Perf Year19.17%
Cash/sh22.63 P/C15.72 EPS next 5Y10.67% ROE20.90% 52W Range196.78 - 404.20 Perf YTD7.21%
Dividend- P/FCF55.65 EPS past 5Y23.20% ROI15.80% 52W High-12.01% Beta0.99
Dividend %- Quick Ratio3.70 Sales past 5Y13.70% Gross Margin70.40% 52W Low80.74% ATR13.98
Employees7700 Current Ratio4.10 Sales Q/Q1.50% Oper. Margin28.40% RSI (14)38.31 Volatility3.33% 2.92%
OptionableYes Debt/Eq0.25 EPS Q/Q-25.20% Profit Margin26.50% Rel Volume4.72 Prev Close399.33
ShortableYes LT Debt/Eq0.14 EarningsAug 06 AMC Payout0.00% Avg Volume903.53K Price355.66
Recom2.30 SMA20-7.94% SMA50-4.37% SMA20011.10% Volume4,265,254 Change-10.94%
Aug-07-20Downgrade Piper Sandler Overweight → Neutral $356 → $340
Aug-07-20Downgrade Evercore ISI In-line → Underperform $310
Jul-07-20Downgrade Guggenheim Buy → Neutral
Apr-24-20Downgrade Citigroup Buy → Neutral $250 → $320
Apr-21-20Downgrade Robert W. Baird Outperform → Neutral $310
Jan-08-20Initiated Wells Fargo Underweight $300
Jan-07-20Initiated Citigroup Buy $385
Jan-02-20Downgrade Evercore ISI Outperform → In-line $330 → $340
Nov-15-19Initiated Stifel Buy
Oct-25-19Initiated Guggenheim Buy $350
Jul-30-19Downgrade Canaccord Genuity Buy → Hold $330 → $300
Jul-12-19Downgrade BofA/Merrill Buy → Underperform
May-30-19Initiated Wolfe Research Outperform
Jan-03-19Upgrade UBS Neutral → Buy
Oct-09-18Initiated UBS Neutral
Aug-07-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jul-31-18Reiterated Canaccord Genuity Buy $330 → $340
Feb-05-18Upgrade Citigroup Neutral → Buy
Jan-31-18Upgrade First Analysis Sec Equal-Weight → Overweight $277
Jan-05-18Initiated BTIG Research Neutral
Aug-07-20 11:40AM  
Aug-06-20 05:30PM  
Aug-04-20 06:40AM  
Aug-03-20 01:49AM  
Jul-30-20 12:33PM  
Jul-28-20 09:48AM  
Jul-27-20 01:01PM  
Jul-25-20 07:30AM  
Jul-22-20 11:23AM  
Jul-21-20 06:08AM  
Jul-17-20 11:40AM  
Jul-16-20 04:05PM  
Jul-12-20 06:12AM  
Jul-08-20 09:01AM  
Jun-30-20 11:18AM  
Jun-29-20 11:40AM  
Jun-25-20 07:49AM  
Jun-23-20 07:19AM  
Jun-19-20 12:01PM  
Jun-18-20 11:06AM  
Jun-17-20 07:01PM  
Jun-16-20 04:05PM  
Jun-12-20 11:40AM  
Jun-10-20 11:49AM  
Jun-09-20 10:36PM  
Jun-08-20 10:22AM  
Jun-05-20 09:47AM  
Jun-03-20 03:47AM  
Jun-01-20 11:00AM  
May-31-20 06:44AM  
May-30-20 11:31AM  
May-27-20 11:40AM  
May-20-20 06:03AM  
May-18-20 04:05PM  
May-14-20 05:45PM  
May-12-20 07:00PM  
May-07-20 11:30AM  
May-06-20 12:10PM  
May-04-20 04:30PM  
May-01-20 07:32PM  
Apr-30-20 09:30PM  
Apr-29-20 09:42AM  
Apr-28-20 09:00AM  
Apr-23-20 12:32PM  
Apr-22-20 12:10PM  
Apr-16-20 04:05PM  
Apr-15-20 03:19PM  
Apr-14-20 04:20PM  
Apr-11-20 09:09AM  
Apr-09-20 11:40AM  
Mar-24-20 11:40AM  
Mar-23-20 05:50PM  
Mar-19-20 03:38PM  
Mar-16-20 06:47AM  
Mar-12-20 11:05AM  
Mar-10-20 09:42AM  
Mar-03-20 05:50PM  
Feb-28-20 11:31AM  
Feb-25-20 07:46AM  
Feb-20-20 04:41PM  
Feb-19-20 02:03PM  
Feb-17-20 05:44PM  
Feb-12-20 04:22PM  
Feb-07-20 07:33AM  
Feb-06-20 03:43PM  
Feb-02-20 08:35AM  
Jan-31-20 10:08AM  
Jan-30-20 05:45PM  
Jan-29-20 05:45PM  
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TOUSI SUSAN HSVP Product DevelopmentAug 05Sale399.03800319,22045,568Aug 06 04:21 PM
Hoyt Aimee LSVP, Chief People OfficerAug 04Sale397.732911,5343,498Aug 05 05:57 PM
FLATLEY JAY TDirectorAug 04Sale397.734,0001,590,920222,933Aug 05 05:54 PM
Van Oene MarkSVP Chief Commercial OfficerAug 03Sale385.43625240,89418,255Aug 05 05:50 PM
Dadswell CharlesSVP & General CounselAug 03Sale385.1912146,6087,913Aug 05 05:41 PM
deSouza Francis APresident and CEOAug 03Sale389.853,0001,169,54374,822Aug 05 04:57 PM
FLATLEY JAY TDirectorJul 21Sale399.004,0001,596,000226,933Jul 22 04:46 PM
TOUSI SUSAN HSVP Product DevelopmentJul 20Sale400.00500200,00046,354Jul 22 04:49 PM
FLATLEY JAY TDirectorJul 07Sale370.224,0001,480,880230,933Jul 08 04:52 PM
TOUSI SUSAN HSVP Product DevelopmentJul 06Sale375.00300112,50046,854Jul 08 04:40 PM
Van Oene MarkSVP Chief Commercial OfficerJul 01Sale369.40625230,87418,880Jul 06 04:25 PM
deSouza Francis APresident and CEOJul 01Sale366.653,0001,099,96078,158Jul 06 04:13 PM
Dadswell CharlesSVP & General CounselJul 01Sale369.2612144,6808,034Jul 06 04:07 PM
FLATLEY JAY TDirectorJun 16Sale354.934,0001,419,720234,933Jun 17 04:18 PM
RAGUSA ROBERT PSVP, Global Quality & OpsJun 15Sale340.765,0001,703,80913,056Jun 17 04:15 PM
Hoyt Aimee LSVP, Chief People OfficerJun 08Sale350.9419167,0303,498Jun 10 05:09 PM
FLATLEY JAY TDirectorJun 02Sale364.404,0001,457,600238,933Jun 03 04:37 PM
deSouza Francis APresident and CEOJun 01Sale362.783,0001,088,32981,158Jun 03 04:34 PM
Van Oene MarkSVP Chief Commercial OfficerJun 01Sale361.54625225,96319,505Jun 03 04:27 PM
Dadswell CharlesSVP & General CounselJun 01Sale362.601,686611,3448,155Jun 03 04:25 PM
TOUSI SUSAN HSVP Product DevelopmentMay 28Sale375.00600225,00047,154Jun 01 04:34 PM
SAMAD SAMSVP and CFOMay 26Sale360.001,356488,1603,879May 28 06:20 PM
TOUSI SUSAN HSVP Product DevelopmentMay 20Sale350.00300105,00047,754May 21 04:51 PM
FLATLEY JAY TDirectorMay 19Sale342.344,0001,369,360241,970May 20 06:48 PM
SAMAD SAMSVP and CFOMay 18Sale340.001,357461,3805,235May 20 06:50 PM
TOUSI SUSAN HSVP Product DevelopmentMay 12Sale325.00600195,00048,054May 13 06:08 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanMay 11Sale315.132,140674,36917,172May 13 06:04 PM
ARNOLD FRANCESDirectorMay 11Sale309.111,503464,5929,954May 13 05:57 PM
FLATLEY JAY TDirectorMay 05Sale310.373,000931,110245,970May 07 05:57 PM
Van Oene MarkSVP Chief Commercial OfficerMay 01Sale316.83625198,01620,130May 05 07:01 PM
deSouza Francis APresident and CEOMay 01Sale308.613,000925,81984,158May 05 06:35 PM
Dadswell CharlesSVP & General CounselMay 01Sale317.1612138,3769,841May 05 06:22 PM
FLATLEY JAY TDirectorApr 21Sale310.773,000932,310248,970Apr 22 04:52 PM
SAMAD SAMSVP and CFOApr 20Sale320.021,356433,9476,592Apr 22 04:54 PM
SAMAD SAMSVP and CFOApr 16Sale300.001,697509,1007,948Apr 20 05:41 PM
Febbo Phillip G.SVP Chief Medical OfficerApr 16Sale300.0017351,9002,490Apr 20 05:39 PM
Van Oene MarkSVP Chief Commercial OfficerApr 16Sale300.221,250375,27520,755Apr 20 05:37 PM
SAMAD SAMSVP and CFOApr 14Sale292.5424972,8429,645Apr 16 04:25 PM
FLATLEY JAY TDirectorApr 07Sale284.632,000569,260251,970Apr 08 05:37 PM
deSouza Francis APresident and CEOApr 06Sale275.003,000825,00087,158Apr 07 04:26 PM
Dadswell CharlesSVP & General CounselApr 01Sale265.9212132,1769,962Apr 03 04:38 PM
Hoyt Aimee LSVP, Chief People OfficerMar 05Sale273.95417114,2373,689Mar 09 05:14 PM
FLATLEY JAY TDirectorMar 03Sale277.402,000554,800256,970Mar 04 04:31 PM
deSouza Francis APresident and CEOMar 02Sale275.003,000825,00090,158Mar 04 04:36 PM
Dadswell CharlesSVP & General CounselMar 02Sale268.021,686451,88210,083Mar 04 04:33 PM
FLATLEY JAY TDirectorFeb 18Sale299.003,000897,000255,970Apr 08 05:37 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanFeb 18Sale298.871,800537,95919,312Feb 20 05:04 PM
MCGINNIS KAREN KVP, Chief Accounting OfficerFeb 11Option Exercise0.001,00104,742Feb 13 08:15 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 11Option Exercise0.0011,641030,166Feb 13 08:12 PM
TOUSI SUSAN HSVP Product DevelopmentFeb 11Option Exercise0.009,969055,574Feb 13 08:10 PM
SAMAD SAMSVP and CFOFeb 11Option Exercise0.006,626014,407Feb 13 08:09 PM
Ronaghi MostafaSVP & CTOFeb 11Option Exercise0.0011,728094,732Feb 13 08:08 PM
RAGUSA ROBERT PSVP, Global Quality & OpsFeb 11Option Exercise0.009,969024,976Feb 13 08:06 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanFeb 11Option Exercise0.0013,488030,643Feb 13 08:05 PM
deSouza Francis APresident and CEOFeb 11Option Exercise0.0035,1840118,817Feb 13 07:39 PM
Dadswell CharlesSVP & General CounselFeb 11Option Exercise0.007,624016,943Feb 13 07:36 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 05Sale300.24625187,65010,623Feb 06 04:23 PM
SAMAD SAMSVP and CFOFeb 03Sale293.1023869,7583,011Feb 05 05:40 PM
RAGUSA ROBERT PSVP, Global Quality & OpsFeb 03Sale293.101,253367,2547,888Feb 05 05:37 PM
TOUSI SUSAN HSVP Product DevelopmentJan 06Sale325.0020065,00038,465Jan 08 04:10 PM
Van Oene MarkSVP Chief Commercial OfficerJan 02Sale330.99625206,86811,178Jan 06 04:12 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanDec 10Sale326.011,200391,2127,844Dec 12 05:13 PM
TOUSI SUSAN HSVP Product DevelopmentDec 06Sale325.001,000325,00038,665Dec 10 04:36 PM
Dadswell CharlesSVP & General CounselDec 02Sale320.33655209,8163,576Dec 04 07:25 PM
Van Oene MarkSVP Chief Commercial OfficerDec 02Sale320.15625200,09411,803Dec 04 07:19 PM
SAMAD SAMSVP and CFONov 29Sale320.00892285,4403,461Dec 03 08:35 PM
Febbo Phillip G.SVP Chief Medical OfficerNov 14Sale300.0015546,5001,506Nov 18 04:33 PM
RAGUSA ROBERT PSVP, Global Quality & OpsNov 01Sale297.281,674497,64710,192Nov 05 04:18 PM
Dadswell CharlesSVP & General CounselNov 01Sale297.2819357,3755,069Nov 05 04:55 PM
Van Oene MarkSVP Chief Commercial OfficerNov 01Sale300.10625187,56313,584Nov 05 04:50 PM
Ronaghi MostafaSVP & CTOOct 15Option Exercise69.344,000277,36080,585Oct 17 04:46 PM
Ronaghi MostafaSVP & CTOOct 15Sale310.934,0001,243,71176,585Oct 17 04:46 PM
Van Oene MarkSVP Chief Commercial OfficerOct 01Sale304.84625190,52514,209Oct 03 04:26 PM
Dadswell CharlesSVP & General CounselOct 01Sale304.2212437,7235,262Oct 03 04:24 PM
Ronaghi MostafaSVP & CTOSep 16Option Exercise69.3410,000693,40086,585Sep 18 05:03 PM
Ronaghi MostafaSVP & CTOSep 16Sale300.5310,0003,005,32376,585Sep 18 05:03 PM
Dadswell CharlesSVP & General CounselSep 03Sale279.881,220341,4545,386Sep 05 04:29 PM
FLATLEY JAY TDirectorAug 28Sale283.413,300935,253262,733Aug 29 04:33 PM
Ronaghi MostafaSVP & CTOAug 15Option Exercise69.3410,000693,40086,585Aug 19 04:50 PM
Ronaghi MostafaSVP & CTOAug 15Sale285.5210,0002,855,20376,585Aug 19 04:50 PM
FLATLEY JAY TDirectorAug 14Sale288.363,300951,588266,033Aug 15 06:31 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanAug 09Sale298.541,260376,16010,685Aug 13 04:10 PM